These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8067197)

  • 1. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
    Skotnicki AB; Wolska-Smoleń T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon-alpha in the treatment of myeloproliferative syndromes].
    Ballarino P; Castello G; Lerza R
    Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.
    Habermann TM
    Oncol Nurs Forum; 1989; 16(6 Suppl):8-11. PubMed ID: 2687814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of interferon in the treatment of chronic myelogenous leukemia.
    Talpaz M
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):3-7. PubMed ID: 7992097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
    Vedantham S; Gamliel H; Golomb HM
    Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
    Mahon FX; Fabères C; Montastruc M; Si-Mour S; Boiron JM; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Pigneux A; Bernard P; Broustet A; Reiffers J
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S33-7. PubMed ID: 8769698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hairy-cell leukemia using interferon alfa].
    Neuwirtová R; Cermák J; Kvasnicka J; Sedlácková M
    Cas Lek Cesk; 1989 Aug; 128(34):1065-70. PubMed ID: 2790914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
    Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The therapeutic effect of interferon-alpha exemplified by hairy cell leukemia].
    Schwarzmeier JD
    Wien Med Wochenschr; 1993; 143(16-17):412-5. PubMed ID: 8273363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
    Appelbaum FR
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha lymphoblastoid in chronic myeloid leukemia patients unresponsive to recombinant IFN alpha 2.
    Steegmann JL; Granados E; Peñarrubia MJ
    Haematologica; 1997; 82(6):731-2. PubMed ID: 9580090
    [No Abstract]   [Full Text] [Related]  

  • 19. alpha-Interferon in hematological malignancies.
    Giles FJ; Ozer H
    Curr Opin Biotechnol; 1991 Dec; 2(6):847-50. PubMed ID: 1367959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon alpha in the treatment of chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Surová M; Kafková A; Guman T; Mudronová B
    Vnitr Lek; 1996 May; 42(5):327-30. PubMed ID: 8768291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.